Suppliers and packagers for FEMARA
✉ Email this page to a colleague
FEMARA
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Novartis Pharms | FEMARA | letrozole | TABLET;ORAL | 020726 | NDA | Novartis Pharmaceuticals Corporation | 0078-0249-15 | 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0078-0249-15) | 1997-07-31 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: FEMARA
Introduction
FEMARA, the brand name for letrozole, is an oral aromatase inhibitor primarily prescribed for hormone receptor-positive breast cancer treatment in postmenopausal women. As a critical medication in oncology, its supply chain quality, reliability, and regulatory compliance directly impact patient outcomes and market stability. This article explores the key suppliers, manufacturing landscape, and considerations for stakeholders in the FEMARA supply chain.
Overview of FEMARA and Its Market
Letrozole—sold under FEMARA and other generics—is a crucial component in breast cancer therapy, targeting estrogen production by inhibiting the aromatase enzyme. The global demand for FEMARA has risen steadily amid increased breast cancer diagnoses. The product’s lifecycle includes initial patent protection leading to proprietary manufacturing, followed by generic entry post-expiry, expanding supply sources and competitive pricing.
Primary Manufacturing and Supply of FEMARA
The original patent for FEMARA was held by Novartis, which had exclusive rights to formulation and marketing until patent expiry. Post-patent, multiple generic pharmaceutical companies entered the market, diversifying supply sources. Leading manufacturers and suppliers can be categorized into original patent holders, authorized generics, and third-party generic producers.
Key Suppliers and Manufacturers
1. Novartis AG
As the innovator, Novartis originally manufactured FEMARA, controlling the supply chain during patent protection. Although patent expiration facilitated generic competition, Novartis retains significant production capacity and global distribution channels through authorized generics and licensing arrangements.
2. Sandoz International GmbH
A division of Novartis, Sandoz is one of the leading suppliers of generic medicines, including letrozole. Sandoz produces high-quality generics that meet stringent regulatory standards, and its global footprint ensures wide distribution of FEMARA and its equivalents.
3. Teva Pharmaceutical Industries Ltd.
Teva is a major player in the generic drug industry, producing letrozole under its own label, providing a reliable, cost-effective alternative to proprietary FEMARA. Teva’s manufacturing facilities are cGMP-compliant, ensuring regulatory approval in multiple jurisdictions.
4. Mylan N.V. (now part of Viatris)
Viatris, formed from the merger of Mylan and Pfizer’s Upjohn unit, supplies generic letrozole products across numerous markets, emphasizing affordability and supply stability. Their extensive manufacturing network supports worldwide distribution.
5. Accord Healthcare / Intas Pharmaceuticals
These Indian-based generic manufacturers produce cost-effective letrozole formulations. They are key suppliers in emerging markets, adhering to international manufacturing standards such as WHO-GMP and US FDA regulations.
6. Other Regional and Local Manufacturers
Numerous regional players in Europe, Asia, and South America produce generic letrozole, often for local markets. These include companies such as Sun Pharmaceuticals (India), Dr. Reddy’s Laboratories, and others, ensuring regional supply diversity.
Regulatory and Quality Considerations
Suppliers must adhere to strict quality standards, including US FDA, EMA, and other local regulatory agencies. Strong regulatory oversight ensures efficacy, safety, and consistent supply. Manufacturers often submit new drug applications (NDAs) or abbreviated new drug applications (ANDAs) to gain approval, demonstrating bioequivalence and manufacturing quality.
Supply Chain Challenges and Trends
-
Patent Expiry and Market Entry: The original patent for FEMARA expired in 2015 in the U.S. (patent number 8,744,049), facilitating widespread generic manufacturing. New entrants enhanced supply resilience but introduced variability in manufacturing sites, increasing regulatory oversight complexity.
-
Manufacturing Reliability: Limitations or disruptions at large facilities—such as quality issues, capacity constraints, or geopolitical factors—can impact supply availability, necessitating diversified sourcing strategies.
-
Geopolitical and Economic Factors: Trade tensions, export restrictions, and pandemic-related disruptions can influence manufacturing and distribution processes, emphasizing the importance of regional manufacturing capabilities.
-
Regulatory Harmonization: Efforts by regulatory authorities, such as mutual recognition agreements (MRAs), aim to streamline approval processes and ensure quality consistency among international suppliers.
Market Dynamics and Opportunities
-
Emerging Markets: Countries like India and China host several regional manufacturers producing generic letrozole, which dominate local markets and offer cost advantages.
-
Brand vs. Generic Competition: Although FEMARA remains the brand, competitive generics influence pricing and supply dynamics, impacting market share and manufacturing priorities.
-
Supply Stability and Security: Healthcare providers and distributors increasingly seek diversified suppliers and strategic stockpiles to mitigate risks from manufacturing disruptions.
Conclusion
The supply of FEMARA hinges on a complex ecosystem of original innovators and a broad spectrum of generic manufacturers. Major players such as Novartis, Sandoz, Teva, Viatris, and regional manufacturers form the backbone of global supply chains. Ensuring continuous, high-quality production requires adherence to regulatory standards and diversification strategies to mitigate geopolitical, logistical, or quality-related risks.
Key Takeaways
More… ↓
